Document is current
Any future updates will be listed below
-
Authors
He, Siyu
Jin, Yinuo https://orcid.org/0000-0003-1889-8587
Nazaret, Achille https://orcid.org/0000-0002-5428-9810
Shi, Lingting
Chen, Xueer https://orcid.org/0000-0002-7503-6388
Rampersaud, Sham https://orcid.org/0000-0001-7473-4144
Dhillon, Bahawar S. https://orcid.org/0009-0005-1825-5356
Valdez, Izabella
Friend, Lauren E.
Fan, Joy Linyue
Park, Cameron Y.
Mintz, Rachel L.
Lao, Yeh-Hsing https://orcid.org/0000-0002-7990-199X
Carrera, David
Fang, Kaylee W.
Mehdi, Kaleem
Rohde, Madeline
McFaline-Figueroa, José L. https://orcid.org/0000-0003-4387-1511
Blei, David
Leong, Kam W.
Rudensky, Alexander Y. https://orcid.org/0000-0003-1280-2898
Plitas, George https://orcid.org/0000-0002-8357-9534
Azizi, Elham https://orcid.org/0000-0001-5059-6971
- License Information
-
More Information
Article History
Received: 21 November 2022
Accepted: 14 February 2024
First Online: 21 March 2024
Competing interests
: A.Y.R. is an SAB member for Coherus, Amgen, Sonoma Biotherapeutics, Santa Ana Bio, Vedanta Biosciences, RAPT Therapeutics and BioInvent. G.P. is an SAB member for Merck, Tizona, Trishula and Paige.AI. A.Y.R. and G.P. have IP on intratumoral Treg cell depletion licensed to Takeda. The other authors declare no competing interests.
